Tag: cabozantinib

September 19, 2018

Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma

Exelixis (NASDAQ:EXEL) today announced that its partner Ipsen Biopharmaceuticals Canada received approval from Health Canada of CABOMETYX (cabozantinib) tablets for the treatment...
September 7, 2018

Exelixis Announces New Recommendations for CABOMETYX (Cabozantinib) Tablets

Exelixis (NASDAQ:EXEL) announced that the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX (cabozantinib)...